98%
921
2 minutes
20
Background: The use of platelet lysate (PL) for the ex-vivo expansion of mesenchymal stromal/stem cells (MSCs) was initially proposed by Doucet et al. in 2005, as an alternative to animal serum. Moreover, regulatory authorities discourage the use of fetal bovine serum (FBS) or other animal derivatives, to avoid risk of zoonoses and xenogeneic immune reactions. Even if many studies investigated PL composition, there still are some open issues related to its use in ex-vivo MSC expansion, especially according to good manufacturing practice (GMP) grade protocols.
Methods: As an authorized cell factory, we report our experience using standardized PL produced by Azienda Ospedaliero Universitaria Meyer Transfusion Service for MSC expansion according to a GMP grade clinical protocol. As suggested by other authors, we performed an in-vitro test on MSCs versus MSCs cultured with FBS that still represents the best way to test PL batches. We compared 12 MSC batches cultured with DMEM 5% PL with similar batches cultured with DMEM 10% FBS, focusing on the MSC proliferation rate, MSC surface marker expression, MSC immunomodulatory and differentiation potential, and finally MSC relative telomere length.
Results: Results confirmed the literature data as PL increases cell proliferation without affecting the MSC immunophenotype, immunomodulatory potential, differentiation potential and relative telomere length.
Conclusions: PL can be considered a safe alternative to FBS for ex-vivo expansion of MSC according to a GMP grade protocol. Our experience confirms the literature data: a large number of MSCs for clinical applications can be obtained by expansion with PL, without affecting the MSC main features. Our experience underlines the benefits of a close collaboration between the PL producers (transfusion service) and the end users (cell factory) in a synergy of skills and experiences that can lead to standardized PL production.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930506 | PMC |
http://dx.doi.org/10.1186/s13287-018-0863-8 | DOI Listing |
NPJ Vaccines
August 2025
International Research Laboratory RESPIVIR France - Canada, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, Canada ; Centre International de Recherche en Infectiologie, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, INSERM, CNRS, EN
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are the main etiologic agents of viral bronchiolitis and pneumonia in children and the elderly. As live-attenuated vaccines (LAV) can stimulate robust mucosal and cellular responses, we previously engineered an HMPV-based bivalent LAV Metavac®-RSV candidate and reported its capacity to protect mice against HMPV and RSV challenges after intranasal delivery. To progress towards clinical development, we identified a GMP-grade Vero cell platform as permissive and efficient to produce high yields of functional Metavac®-RSV, expressing both RSV and HMPV F antigen after several passages.
View Article and Find Full Text PDFBMJ Open
August 2025
EGA Institute for Women's Health, University College London, London, UK
Introduction: Neonatal death and later disability remain common sequelae of hypoxic-ischaemic encephalopathy (HIE) despite the now standard use of therapeutic hypothermia (HT). New therapeutic approaches to brain protection are required. Melatonin is an indolamine hormone with free-radical scavenging, antiapoptotic, anti-inflammatory and gene regulatory neuroprotective properties, which has extensive preclinical evidence of safety and efficacy.
View Article and Find Full Text PDFJ Hazard Mater
September 2025
Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, Jiangsu 214122, China. Electronic address:
Bioleaching is a critical approach for processing low-grade copper ores, relying on the "contact" mechanism mediated by microbial extracellular polymeric substance (EPS) secretion and biofilm formation. In the typical leaching microorganism Acidithiobacillus caldus, there is a transcriptional regulatory factor EpsR that regulates EPS secretion. It has a typical PilZ domain that binds cyclic diguanylate (c-di-GMP) and can sense Cu to relieve its own repression.
View Article and Find Full Text PDFPharmaceutics
June 2025
SOMAÍ Pharmaceuticals, R. 13 de Maio 52, 2580-507 Carregado, Portugal.
The industrial extraction and purification processes of L. compounds are critical steps in creating formulations with reliable and reproducible therapeutic and sensorial attributes. For this study, standardized preparations of chemotype I were chemically analyzed, and the sensory attributes were studied to characterize the extraction and purification processes, ensuring the maximum retention of cannabinoids and minimization of other secondary metabolites.
View Article and Find Full Text PDFInt Rev Cell Mol Biol
July 2025
Cell Therapy, Stem Cells and Tissue Group, Biobizkaia Health Research Institute, Barakaldo, Spain; Advanced Therapies Unit. Basque Center for Blood Transfusion and Human Tissues, Osakidetza, Galdakao, Spain; Red de Inmunoterapia del Cáncer "REINCA", Madrid, Spain. Electronic address: maite.alvarezr
Cytokines are crucial modulators of immune responses and have emerged as key components in cancer immunotherapy, particularly concerning Natural Killer (NK) cells. Indeed, the administration of these cytokines have demonstrated significant therapeutic potential in clinical settings. For instance, interleukin-2 (IL-2) has shown efficacy in melanoma and renal cell carcinoma, enhancing anti-tumor immunity but often associated with dose-limiting toxicities.
View Article and Find Full Text PDF